INTRODUCTION

Oprelvekin (brand name Neumega) is a recombinant Interleukin-11 (IL-11) that is used to stimulate production of megakaryocytes and platelets in patients with or at risk of thrombocytopenia after chemotherapy.

This plasmid is designed for expressing Oprelvekin in E.coli expression system.

PRODUCT INFORMATION

Item No.: PPBD-133
Shipping: Lyophilized plasmid, or liquid plasmid, or plasmids on filter paper
Storage: -20 °C or 4°C according to instruction
Plasmid Backbone: Expression plasmid, flexible options, custom available
Quality Control: Sequencing validation

DRUG INFORMATION

Generic Name: Oprelvekin
Brand Name(s): Neumega
Classification: Interleukins
Amino Acid Sequence: Identical to DB00038

PROTOCOL FOR PLASMID RECOVERY FROM FILTER PAPER

REFERENCE

[1] Cantor SB, Elting LS, Hudson DV Jr, Rubenstein EB. Pharmacoeconomic analysis of oprelvekin (recombinant human interleukin-11) for secondary prophylaxis of thrombocytopenia in solid tumor patients receiving chemotherapy. Cancer. 2003 Jun 15;97(12):3099-106.

[2] Wilde MI, Faulds D. Oprelvekin: a review of its pharmacology and therapeutic potential in chemotherapy-induced thrombocytopenia. BioDrugs. 1998 Aug;10(2):159-71.

Contact Us